OBJECTIVES: The aim of this study was to evaluate the effect of statins in decreasing cardiovascular events in women and men. BACKGROUND: Published data reviews have suggested that statins might not be as effective in women as in men in decreasing cardiovascular events. METHODS: Published data searches and contacts with investigators identified 18 randomized clinical trials of statins with sex-specific outcomes (N = 141,235, 40,275 women, 21,468 cardiovascular events). Odds ratios (ORs) and 95% confidence intervals (CIs) for cardiovascular events were calculated for women and men separately with random effects meta-analyses. RESULTS: The cardiovascular event rate was lower among those randomized to statin intervention than in those randomized to control (low-dose statin in 4 studies, placebo in 11 studies, usual care in 3 studies) and similar in women and men (OR: 0.81, 95% CI: 0.75 to 0.89; p < 0.0001, and OR: 0.77, 95% CI: 0.71 to 0.83, p < 0.0001, respectively). The benefit of statins was statistically significant in both sexes, regardless of the type of control, baseline risk, or type of endpoint and in both primary and secondary prevention. All-cause mortality was also lower with statin therapy both in women and men without significant interaction by sex (p for interaction = 0.4457). CONCLUSIONS: Statin therapy is associated with significant decreases in cardiovascular events and in all-cause mortality in women and men. Statin therapy should be used in appropriate patients without regard to sex.
OBJECTIVES: The aim of this study was to evaluate the effect of statins in decreasing cardiovascular events in women and men. BACKGROUND: Published data reviews have suggested that statins might not be as effective in women as in men in decreasing cardiovascular events. METHODS: Published data searches and contacts with investigators identified 18 randomized clinical trials of statins with sex-specific outcomes (N = 141,235, 40,275 women, 21,468 cardiovascular events). Odds ratios (ORs) and 95% confidence intervals (CIs) for cardiovascular events were calculated for women and men separately with random effects meta-analyses. RESULTS: The cardiovascular event rate was lower among those randomized to statin intervention than in those randomized to control (low-dose statin in 4 studies, placebo in 11 studies, usual care in 3 studies) and similar in women and men (OR: 0.81, 95% CI: 0.75 to 0.89; p < 0.0001, and OR: 0.77, 95% CI: 0.71 to 0.83, p < 0.0001, respectively). The benefit of statins was statistically significant in both sexes, regardless of the type of control, baseline risk, or type of endpoint and in both primary and secondary prevention. All-cause mortality was also lower with statin therapy both in women and men without significant interaction by sex (p for interaction = 0.4457). CONCLUSIONS: Statin therapy is associated with significant decreases in cardiovascular events and in all-cause mortality in women and men. Statin therapy should be used in appropriate patients without regard to sex.
Authors: Saad B Omer; Varun K Phadke; Robert A Bednarczyk; Allison T Chamberlain; Jennifer L Brosseau; Walter A Orenstein Journal: J Infect Dis Date: 2015-10-28 Impact factor: 5.226
Authors: Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham Journal: Hear Res Date: 2020-02-06 Impact factor: 3.208